Key facts
- This page summarizes Jorey Chernett's Form 4 filing for Starling Oncology, Inc. (STLN).
- 6 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 10 Nov 2026, 18:33.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Purchase
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Purchase
Purchase
Purchase
Purchase
Additional SEC filing notes
Footnote F1
The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were sold in multiple transactions at prices ranging from $3.38 to $5.21, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price such shares were sold.
Footnote F2
The reported transactions are matchable transactions subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer.
Footnote F3
The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.53 to $3.91, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.
Footnote F4
The price reported in Column 8 is a weighted average price. These Call Options were purchased in multiple transactions at prices ranging from $0.4998 to $0.55, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Call Options purchased at each separate price such Call Options were purchased.